Last edition
News about "cancer immunotherapy"
FDA Grants ODD to Leukogene Therapeutics' M2T-CD33 (LTI-214) for Treating Acute Myeloid Leukemia
The US FDA has granted ODD to Leukogene Therapeutics’ M2T-CD33 (LTI-214) for the treatment of Acute Myeloid Leukemia (AML). The designation highlights the pressing need for new treatment options and acknowledges LTI-214’s potential as a novel and targeted therapy for this aggressive form of blood cancer.
Cancer Immunotherapy | 05/11/2025 | By Dineshwori
TuHURA Biosciences Signs Exclusivity and Right of First Offer Deal for Kineta
TuHURA Biosciences, Inc. has entered into an Exclusivity and Right of First Offer Agreement with Kineta, Inc. for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody and related rights and assets associated with and derived from the asset.
Cancer Immunotherapy | 09/07/2024 | By Aishwarya | 456
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy